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Vascular dysfunction is thought to play a major role in the development of diabetic cardiovascular dis-
ease. The roles of endothelial dysfunction, oxidative stress, and dyslipidemia will be considered. Mela-
tonin as well as L-carnitine were shown to possess strong antioxidant properties. Diabetes induced with
high fat diet (for 8 weeks) and multipl low doses intraperitoneal injection of STZ (twice, 30 mg/kg/d i.p).
The diabetic animals were randomly assigned to one of the experimental groups as follows: Control
group (C), high fat diet (HFD), STZ-induced diabetic group (HFDþSTZ) , HFDþSTZ diabetic group re-
ceived melatonin (10 mg/kg/d i.p), HFDþSTZ diabetic group received L-carnitine (0.6 g/kg/d i.p), and
HFDþSTZ diabetic group received glibenclamide (5 mg/kg/d, oral). The serum fasting blood glucose,
insulin, total cholesterol, HDL- cholesterol, LDL-cholesterol, triglyceride and malondialdehyde (MDA)
levels were tested. Acetylcholine induced endothelium-dependent relaxation and sodium nitroprusside
induced endothelium-independent relaxation were measured in aortas for estimating endothelial
function. Also, glutathione peroxidase (GPx), superoxide dismutase (SOD) and nitric oxide (NO) levels
activities were determined in rat liver. According to our results melatonin and L-carnitine treatment
decreased fasting blood glucose, total cholesterol, and LDL levels. MDA levels signiﬁcantly decreased with
the melatonin treatment whereas SOD levels were not signiﬁcantly changed between the groups. The
results suggest that especially melatonin restores the vascular responses and endothelial dysfunction in
diabetes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Diabetes Mellitus is a metabolic as well as vascular disease
which causes important complications with gradually increasing
frequency all over the world. Formation of the free radicals and
association between oxidative stress and diabetes complications
have recently gained importance in the ﬁeld old diabetes.
It is well known that the interaction between free oxygen ra-
dicals and nitric oxide (NO) cause formation of peroxynitrite and,
this cytotoxic oxidant leads to endothelial dysfunction by impair-
ing the function of cellular proteins through the nitration of pro-
teins. Endothelial dysfunction plays a role in especially NO bioa-
vailability of vasodilators, impaired endothelium dependent va-
sodilation or increased endothelium derived contracting factors,B.V. This is an open access article u
lmanoglu),
oo.com (K. Vural),
mynet.com (E. Darıverenli),resulting in emergence of diabetes complications [1].
L-Carnitine (3-Hydroxy 4-N-trimethylammonio – butyrate) is
an amino acid-like agent involved in the transit of long chain fatty
acids which are physically synthesized in the various tissues in
living organisms and will be transferred from cytoplasm to the
mitochondria matrix, through the inner mitochondrial membrane.
In diabetic experimental animals, carnitine levels of pancreas have
been found to decrease both in early and advanced stages of dia-
betes and excretion of carnitine with urine to increase [2]. There
are studies suggesting that insulin sensitivity and use of glucose by
peripheral tissues increase [3,4]. In the studies conducted with
hypertensive and normotensive rats, L-carnitine has been de-
monstrated to induce endothelium dependent relaxation by in-
creasing the production of nitric oxide [5].
Melatonin is one of the known most potent antioxidants and
recent studies indicate that melatonin receptors found in the
pancreas islet cells might be protective against harmful outcomes
of hyperglycemia [6]. In the other studies, L-carnitine has beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diabetic rats induced with STZ [7].1. Experimental procedures
1.1. Animal model and experimental groups
Thirty ﬁve male Wistar rats (250–350 g) had access to labora-
tory food and water ad libitum. They were housed in cages under
standard laboratory conditions (light period between 07:00–
19:00 h, 21_2 °C; relative humidity 55%). This study was approved
by the Institutional Animal Care Ethics Committee of Ege Uni-
versity, Turkey (2010/137).
The diabetic rat model was developed using a high-fat diet plus
multiple low doses of streptozotocin which was similar to that
employed in previously studies [8]. The high-fat diet consisted of
22% fat, 48% carbohydrate, and 20% protein with total caloriﬁc
value 44.3 kJ/kg ( Bilgen Lab. Istanbul, Turkey) and control rats
were given regular chow consisting of 5% fat, 53% carbohydrate,
and 23% protein with total caloriﬁc value 25 kJ/kg. Following
4 weeks of dietary intervention, the diabetic group was injected
intraperitoneally (i.p.) with low doses of streptozotocin (Sigma, St.
Louis, MO, USA, 30 mg/kg, dissolved in 0.1 M sodium citrate buffer,
pH 4.4). One week later, blood samples were collected by tail
cutting for fasting blood glucose measurements were measured by
(Accu-Chek Active-glucometer). Rats with a fasting blood glucose
of 7.8 mmol/L were injected with streptozotocin again (30 mg/kg).
Control rats were given vehicle citrate buffer (pH 4.4) in a matched
volume (0.25 ml/kg) via intraperitoneal injection. 4 weeks after
the streptozotocin injection, the fasting blood glucose was mea-
sured again, and rats with a fasting blood glucose of Z7.8 mmol/L
were considered diabetic [9]. The diabetic rats were fed the high-
fat diet for another 4 weeks, the control and diabetic rats were
then randomly divided into 5 groups: [1] control group (CONN,
rats treated with saline in a matched volume), [2] Non treated
diabetic group (HFDþSTZ ), [3] L-carnitine treated diabetic group
(HFDþSTZ þLC, 0.6 g/kg/d, oral), [4] melatonin treated diabetic
group (HFDþSTZ þMLT, 10 mg/kg/d, i.p) and [5] glibenclamide
treated diabetic group (HFDþSTZþGB, 5 mg/kg/d, i.p.). Melatonin
and L-carnitine were dissolved in distillated water and adminis-
tered intraperitoneally glibenclamide was administrated via oral
gavage daily for 2 weeks [10–12]. All the rats were allowed to
continue to feed on their respective diets until the end of the
study.
1.2. Vasocontractile responses
At the end of treatment, the animals were anesthetized by
using an intraperitoneal injection urethane (1000 mg/kg, 20%)
after fasting 12 h. Thoracic aorta was removed, placed in cold
Krebs-Henseleit solution, cleaned gently of adherent connective
tissue and cut into rings (approximately 3 mm length). Blood
samples from abdominal aorta and also liver tissue samples were
collected, when rats were killed, for the measurement of glucose,
insulin, NO, lipid metabolic parameters and some antioxidant
enzyme levels.
General parameters of rats (fasting blood glucose and body
weight) were measured and recorded at the beginning, before the
melatonin and L–carnitine treatment and at the end of
experiment.
The aortic rings were suspended under a resting tension 1 g in
20 ml organ chambers containing oxygenated (5% CO2, 95% O2)
and warmed (37'C) Krebs solution (pH: 7.4) with the following
composition (mM): NaCl 112, KCl 5, NaHCO3 25, NaH2PO4 1,
MgCl2 0.5, CaCl2 2.5 and glucose 11.5. All preparations were ﬁxedwith two stainless steel wires, one was connected to a force dis-
placement transducer (MAY FDT 05, COMMAT Ltd., Ankara, Tur-
key) for the measurement of isometric contractions and for record
on computer using transducer data acquisition system (TDA 94,
COMMAT).
After 1 h washing and equilibration period, contractile re-
sponses to phenylephrine were taken in rings to determine pre-
contractile tone in vessels. Relaxations induced by acetylcholine
(109–105 M ) and sodium nitroprusside (109–105 M) were
obtained from aortic rings precontracted with EC80 concentration
of phenylephrine. To determine endothelium-dependent relaxa-
tion induced by NO, the contractile responses to NG-nitro-L-argi-
nine (L-NAME) (102 M) were recorded in rings precontracted
with EC50 concentration of phenylephrine.
1.3. Measurement of total cholesterol, LDL, HDL, triglyceride, glucose,
NO and insulin
The plasma was prepared with EDTA and separated by cen-
trifugation (10 min, 3000 rpm). Plasma total cholesterol, trigly-
ceride and high-density lipoprotein (HDL) were measured by a
commercially available enzyme kit. Plasma LDL was determined
using the Friedewald formula: LDL cholesterol¼Total cholesterol-
HDL-Triglyceride/5 [13]. The concentration of plasma glucose was
measured using a glucose kit based on the glucose oxidase
method. Insulin was measured by a rat insulin ELISA kit (Millipore,
Merck). A nitric oxide ﬂuorometric assay kit (Cayman Chemical,
USA) that provides measurement of total nitrate/nitrite con-
centration was used to assay plasma NO levels.
1.4. MDA assay
The malondialdehyde (MDA) assay was conducted by the
thiobarbituric acid method in liver homogenates and plasma. The
MDA levels were determined using a molar extinction coefﬁcient
of 1.56105 M1 cm1.
1.5. Measurement of tissue antioxidant levels
Liver tissues were washed in 0.9% NaCl solution and approxi-
mately 0.5 g tissue samples of liver were homogenized in 0.15 M
KCl- 10 mM potassium phosphate buffer, pH:7,4 [tissue to buffer
ratio, 1:10 w/v]. Homogenized samples were centrifuged (13000 g,
10 min.) and stored at 80'C until analysis.
Glutathione peroxidase and superoxide dismutase levels in li-
ver tissues were assayed using commercially speciﬁc kits (Cayman
chemical, USA) and liver catalase activity was determined as de-
scribed by Aebi [14].
1.6. Statistical analyses
Statistical analyses were performed using SPSS 16.00 for win-
dows software. Data were expressed as arithmetic mean7-
standard error (SE) in n number subjects. Difference between the
values was considered statistically signiﬁcant if p valueo0.05. One
way variance (Anova) analysis was used in evaluation of the iso-
metric vascular responses and post hoc tukey test was used in
comparison of the data having signiﬁcance. Other non-normal
distribution data of the experimental animals were subjected to
nonparametric testing. Accordingly, ﬁrst Kruskal–Wallis test was
carried out and in case of difference between the groups Mann–
Whitney U test was performed. Variance analysis was made in
order to deﬁne differences and signiﬁcances in the repeating
measures (fasting blood glucose, body weight etc.).
Table 2
Fasting blood glucose values of the experiment animals
Groups Initial fasting
blood glucose
(mg/dl)
Fasting blood glu-
cose (mg/dl after
STZ/(i.p) (5th
week))
Final fasting
blood glucose
(mg/dl)
C (n¼7) 107.8973.50 103.2273.24 105.4473.40
HFDþSTZ (n¼7) 101.0072.73 271.80737.27a 289.70740.21a
HFDþSTZþMLT
(n¼7)
106.2574.05 318.00752.53a 259.63754.59a,b
HFDþSTZþLC
(n¼7)
101.8675.20 281.57756.21a 188.57740.77b
HFDþSTZþGB
(n¼7)
112.1372.48 334.63757.23a 280.63760.37a,b
Controls were abbreviated as (C), untreated diabetic group as (HFDþSTZ ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitin 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). Groups'
baseline weights and the body weights following 4-week HFD, one week after
streptozotocin injection and at the end of the experiment are given. The results are
shown as Values7SEM and n¼shows the number of animals in the group
a po0.05 statistical signiﬁcance of the same group compared to baseline.
b po0.05 statistical signiﬁcance of the same group compared to the 5th week
value.
Fig. 1. Contraction responses obtained with phenylephrine in vascular strips.
Controls were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitine 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). The results
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2.1. General parameters
Body weight and fasting blood glucose changes in normal and
diabetic rats were shown in Tables 1 and 2. Body weight values
were signiﬁcantly increased after diabetes induced period by
(HFDþSTZ) and at the end of experiment in all groups except
L-carnitine treated group (po0.05). Final body weights sig-
niﬁcantly decreased in L-carnitine and melatonin treated groups
compared with untreated diabetic group in 5th week. (po0.05).
Fasting blood glucose concentration of untreated diabetic rats
were higher compared with those of control group (po0.05). L-
carnitine and melatonin treatment has ameliorative effect on
blood glucose levels. In these groups, blood glucose levels sig-
niﬁcantly decreased after L-carnitine and melatonin treatment
compared with 5th week levels and untreated diabetic group
(po0.05).
2.2. Vascular activity
Phenylephrine induced contractile responses in control and
diabetic aorta are shown in Fig. 1. There was no signiﬁcant dif-
ference between groups in contractility and also sensitivity of
phenylephrine. Acetylcholine induce relaxation was signiﬁcantly
decreased in untreated diabetic group compared with control
group (po0.05). L-carnitine and melatonin treatment signiﬁcantly
impaired the diabetes-induced decrease in acetylcholine relaxa-
tions (po0.05; Fig. 2).
Relaxation responses of sodium nitroprusside showed no dif-
ference between groups. L-NAME contractions decreased in dia-
betic aortas compared to control group but there is no statistically
signiﬁcant difference between treated and untreated diabetic
groups. Fig. 3 and Fig. 4
2.3. Lipid peroxidation and antioxidant status
Blood lipid proﬁle in all groups are shown in Table 3. Induction
of diabetes signiﬁcantly increased total cholesterol levels in dia-
betic group and this increase was signiﬁcantly reversed by L-car-
nitine treatment (po0.05) LDL cholesterol levels were sig-
niﬁcantly decreased in L-carnitine treated group compared with
untreated diabetic group. Triglyceride and HDL cholesterol levelsTable 1
Body weight values of the experiment animals.
Groups Initial body
weight (g)
Body weight after
STZ/vehicle (i.p)
(5th week)
Final body weight
(g)
C (n¼7) 214.4476.09 240.5679.41a 281.11715.65a,b
HFDþSTZ (n¼7) 228.0075.17 251.00713.51a 250.00715.15
HFDþSTZþMLT
(n¼7)
220.0078.07 242.5079.45a 227.5078.07b
HFDþSTZþLC
(n¼7)
235.0077.94 267.14717.52 223.57712.80b
HFDþSTZþGB
(n¼7)
221.2579.62 254.38712.15a 240.00714.48
Controls were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitin 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). Groups’
baseline weights and the body weights following 4-week HFD, one week after
streptozotocin injection and at the end of the experiment are given. The results are
shown as Values7SEM and n¼shows the number of animals in the group,
a po0.05 statistical signiﬁcance of the same group compared to baseline.
b po0.05 statistical signiﬁcance of the same group compared to the 5th week
values.
are shown as Values7SEM n¼7 in all the groups.were slightly increased in untreated diabetic group, but this dif-
ference has no statistical signiﬁcance. The plasma insulin levels
signiﬁcantly decreased in all diabetic groups compared to control
group. (Fig. 5) Insulin levels were slightly increased in glib-
enclamide treated diabetic group but this difference has no sta-
tistical signiﬁcance.
NO levels in diabetic rats were lower than other groups.
L-carnitine and melatonin treatment reversed this decrease in
plasma NO levels but only in glibenclamide treated group this is
statistically signiﬁcant (Fig. 6). The plasma MDA level in diabetic
group was higher than control group and L-carnitine, melatonin
and glibenclamide treated groups improved the diabetes-induced
increase in plasma MDA levels (Fig. 7). However only in melatonin
treated group treatment this increase found statistically signiﬁcant
(po0.05). Neither diabetes induction nor treatment has no effect
on the liver SOD levels (Fig. 8).
The liver glutathione peroxidase (GPx) activity was signiﬁcantly
decreased in diabetic group and increased in L-carnitine, melato-
nin and glibenclamide treated groups (Fig. 9). However only in
glibenclamide treated group treatment this increase found
Fig. 2. Relaxation responses obtained with acetylcholine in vascular strips.Controls
were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic group
treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group treated
with L-carnitine 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated with
glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). The results are
shown as Values7SEM n¼7 in all the groups. *po0.05 shows the signiﬁcance
compared to the controls.
Fig. 3. Relaxation responses obtained with sodium nitroprusside in vascular strips.
Controls were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitine 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). The results
are shown as Values7SEM n¼7 in all the groups.
Fig. 4. Contractile responses to L-NAME (100 micro M) presented as the percentage
of phenylephrine precontraction in endothelium intact thoracic aortic rings. Con-
trols were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitine 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). The results
are shown as Values7SEM n¼7 in all the groups.
Table 3
Lipid values obtained from blood samples
Groups Total choles-
terol (mg/dl)
Triglyceride
(mg/dl)
HDL-cho-
lesterol
(mg/dl)
LDL-choles-
terol (mg/dl)
C 27.7172.62 36.4373.45 9.007 .82 14.7172.20
HFDþSTZ 47.7172.86a 64.29716.87 11.577 .95 20.1472.43
HFDþSTZþMLT 37.7175.23 58.29713.11 10.8872.22 15.0073.19
HFDþSTZþLC 33.2971.90b 56.4378.49 10.717 .48 10.5771.76 b
HFDþSTZþGB 39.4372.75 55.0077.61 11.0071.07 15.1471.62
Controls were abbreviated as (C), untreated diabetic group as (HFDþSTZ), diabetic
group treated with melatonin 10 mg/kg/day as (HFDþSTZþMLT), diabetic group
treated with L-carnitin 0.6 g/kg/day as (HFDþSTZþLC) and diabetic group treated
with glibenclamide 5 mg/kg/day was abbreviated as (HFDþSTZþGB). The results
are shown as Values7SEM n¼7 in all the groups.
a po0.05 shows the statistical signiﬁcance compared to the controls.
b po0.05 shows the statistical signiﬁcance compared to the untreated diabetic
group.
Fig. 5. Serum Levels of Insulin. Controls were abbreviated as (C), untreated diabetic
group as (HFDþSTZ), diabetic group treated with melatonin 10 mg/kg/day as
(HFDþSTZþMLT), diabetic group treated with L-carnitine 0.6 g/kg/day as
(HFDþSTZþLC) and diabetic group treated with glibenclamide 5 mg/kg/day was
abbreviated as (HFDþSTZþGB). The results are shown as Values7SEM n¼7 in all
the groups. *po0.05 shows the signiﬁcance compared to the controls.
Fig. 6. Serum Levels of NO. Controls were abbreviated as (C), untreated diabetic
group as (HFDþSTZ), diabetic group treated with melatonin 10 mg/kg/day as
(HFDþSTZþMLT), diabetic group treated with L-carnitine 0.6 g/kg/day as
(HFDþSTZþLC) and diabetic group treated with glibenclamide 5 mg/kg/day was
abbreviated as (HFDþSTZþGB). The results are shown as Values7SEM n¼7 in all
the groups. *po0.05 shows the statistical signiﬁcance compared to the controls,
#po0.05 shows the statistical signiﬁcance compared to the untreated diabetic
group.
Fig. 7. Serum Levels of MDA. Controls were abbreviated as (C), untreated diabetic
group as (HFDþSTZ), diabetic group treated with melatonin 10 mg/kg/day as
(HFDþSTZþMLT), diabetic group treated with L-carnitine 0.6 g/kg/day as
(HFDþSTZþLC) and diabetic group treated with glibenclamide 5 mg/kg/day was
abbreviated as (HFDþSTZþGB). The results are shown as Values7SEM n¼7 in all
the groups. *po0.05 shows the statistical signiﬁcance compared to the controls,
#po0.05 shows the statistical signiﬁcance compared to the untreated diabetic
group.
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Fig. 8. Liver Levels of SOD. Controls were abbreviated as (C), untreated diabetic
group as (HFDþSTZ), diabetic group treated with melatonin 10 mg/kg/day as
(HFDþSTZþMLT), diabetic group treated with L-carnitine 0.6 g/kg/day as
(HFDþSTZþLC) and diabetic group treated with glibenclamide 5 mg/kg/day was
abbreviated as (HFDþSTZþGB). The results are shown as Values7SEM n¼7 in all
the groups.
Fig. 9. Liver Levels of GPx. Controls were abbreviated as (C), untreated diabetic
group as (HFDþSTZ), diabetic group treated with melatonin 10 mg/kg/day as
(HFDþSTZþMLT), diabetic group treated with L-carnitine 0.6 g/kg/day as
(HFDþSTZþLC) and diabetic group treated with glibenclamide 5 mg/kg/day was
abbreviated as (HFDþSTZþGB). The results are shown as Values7SEM n¼7 in all
the groups. *po0.05 shows the statistical signiﬁcance compared to the controls,
#po0.05 shows the statistical signiﬁcance compared to the untreated diabetic
group.
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Objective of this study was to create an experimental model
which was the closest to Type 2 DM characteristics and to in-
vestigate antioxidant features of melatonin which is known to
have a potent antioxidant feature and L-carnitine which has not
been well studies agent and, their effects on the vascular
responses.
High-fat diet was used in Type 2 diabetes model in order to
induce insulin resistance. Since in the case of this method was
combined with multiple low dose STZ, beside insulin resistance
insulin deﬁciency would also develop, this model was considered
as a proper Type 2 diabetes animal model. Results of a recent rats
fed with HFD to create experimental diabetes through various
doses of STZ demonstrated that, administration of multiple low
dose STZ (30 mg/kg i.p. weekly, for 2 weeks) created an obvious
hyperglycemia with a high success rate.
Likewise, in this study 4-week HFD and STZ injection were
observed to create an obvious hyperglycemia. In the conducted
studies, a signiﬁcant decrease has been observed in the plasma
levels of carnitine in human and rats this decrease suggested that
carnitine plays an important role in diabetic complications [10,15].
As it was demonstrated in this study, effects of L-carnitine on the
blood levels of glucose in diabetic rats were consistent with the
previous studies and showed its partial decreasing effect. There
are also studies suggesting carnitine increases or does not change
the blood glucose [16]. In the studies which demonstrated that
melatonin failed to normalize hyperglycemia and body weight in
STZ-induced diabetes, in this study also melatonin decreased but
failed to normalize the blood glucose [17]. In addition, in this study
serum levels of MDA was found to be lower in the treatedcompared to untreated diabetic group only decrease observed in
the group treated with MLT was considered as statistically sig-
niﬁcant. There are conﬂicting studies in the literature reporting
SOD levels increased, did not change or decreased in diabetes
[18,19].
In our study no signiﬁcant change was observed in the levels of
SOD which is an important marker for the oxidative stress. The
levels of another oxidative stress marker, GPx levels were found to
be higher than the controls, but glibenclamide therapy was ob-
served to increase the level GPx by the highest rate. In addition, in
this study triglyceride values of the untreated diabetic group were
found to be signiﬁcantly higher than the controls in terms of blood
lipid levels. Triglyceride and LDL cholesterol levels were sig-
niﬁcantly decreased in the group administered L-carnitine therapy.
Melatonin was found not to signiﬁcantly affect blood lipid levels,
consistently with the other studies [20]. In another study in-
vestigating effects of HFD and single low-dose STZ on rats, again
low dose STZ administration was observed not to change plasma
insulin values, feed with HFD alone to increase insulin levels and
the combined administration to decrease insulin levels [21].
Whereas data obtained from this study demonstrated that insulin
levels were signiﬁcantly decreased in all the treated and untreated
diabetic rats compared to the controls except glibenclamide group.
Endothelium dependent relaxation responses which occur with
acetylcholine is impaired in various vascular beds in the Type
2 diabetes animal models and patients. Acetylcholine shows its
relaxation affect by providing release of the relaxation factors such
as NO and prostacyclin and endothelium-derived hyperpolariza-
tion factor (EDHF). Abnormal production or response of NO con-
tributes to the vascular and endothelial dysfunction seen in
diabetes.
Consistently with the previous studies, in this study it was seen
that, Ach-induced endothelium dependent relaxing response was
decreased, but no any change was observed in the sensitivity in
aorta of the rats. Acetylcholine induced endothelium dependent
relaxation is an effect under control of the muscarinic receptor and
post receptor events are more potent in the impaired response
rather than the receptor mechanisms in the endothelial cells.
Possible mechanism of the decrease in acetylcholine induced en-
dothelium dependent relaxation response might be due to highly
increased of the free radical formation in the diabetic area might
decrease effect of NO. It has been reported in the previous studies
that, free radicals and partially superoxide and hydroxyl radicals
interact with NO, resulting with formation of less potent vasodi-
lators such as peroxynitrite NO2 and NO3. This products may be
accounted for the impairment in endothelium dependent relaxa-
tion response.
In this study L-carnitine, melatonin and glibenclamide therapy
partly normalized endothelium dependent relaxation response
against acetylcholine in the diabetic aortas. Contraction responses
against L-NAME were signiﬁcantly decreased in the diabetic rat
aortas. These results show that, impairment of endothelium de-
pendent relaxation response in the aortas of STZ induced diabetic
rats STZ fed with HFD is mainly a NO mediated event.
Sodium nitroprusside (SNP) directly affects vascular smooth
muscle by increasing guanylate cyclase activity and creates a re-
laxation independently form endothelium. In our study, no any
change was observed in the responses against SNP. This result
indicated that response of the vascular smooth muscle against NO
did not change in the diabetic aorta and actual harmful effect of
diabetes was on the endothelium cells. Melatonin improved the
impairment in endothelium dependent relaxation induced by
acetylcholine, but did not create ant change in SNP induced en-
dothelium independent relaxation in the aortas of diabetic rats.
In conclusion, melatonin therapy decreased oxidative stress
and MDA levels that was increased in diabetes and increased the
D.S. Salmanoglu et al. / Redox Biology 8 (2016) 199–204204low NO levels. Whereas L-carnitine partly decreased blood glucose
levels and lipid parameters in diabetic rats. L-carnitine therapy
partly decreased the severity of hyperglycemia and this improve-
ment was seen to be directly correlated with the partly improve-
ment in endothelium dependent relaxation in the diabetic aorta.
In light of these results, we believe that melatonin and L-carnitine
could be helpful in prevention the complications related to Type
2 diabetes and its treatment.References
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